During FY 2013-14, the company's revenue stood at Rs 310 crore as compared to Rs 299.83 crore in the previous fiscal. Despite a marginal growth of 3.39 percent, Bharat Biotech is expected to perform exceptionally well in the coming years owing to much stronger product portfolio.

Bharat Biotech is the only company in India to attain approval of the Korea Food and Drugs administration. The core focus of the company is to develop novel healthcare solutions for rare and neglected diseases. The company continues to leave a mark in the domain of disease prevention by researching, manufacturing, and marketing newer vaccines. With over 50 technology-driven patents, the company is involved in quality product-oriented research and development.

The major milestone of the company, in recent times, has been the successful completion of the Rotavirus vaccine development program. The vaccine, Rotavac, developed by Bharat Biotech was put at an exceptionally lower price of $1 per dose and has now recently been included in India's Universal Immunization Program (UIP).

Bharat Biotech has continued to embark on its vaccines, launching newer ones to tame epidemics like Japanese encephalitis and Typhoid. The launch of world's first clinically proven typhoid conjugate vaccine Typbar-TCV, a fourth generation vaccine against typhoid in August, 2013, has been lauded as a great achievement. In October, 2013, Bharat Biotech launched its Vero cell- derived purified inactivated JE vaccine, JENVAC. It is a fully indigenous vaccine and provides long term sero-protection.

The company has also been a part of many CSR initiatives. As a noble gesture for the Andhra Pradesh gas explosion victims, Bharat biotech has donated 500 tubes of Regen-D, a wound healing drug to the chief minister's relief fund.